Vimarsana
Biggest News Aggregation in the World

Page 45 - Emergency Task News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Emergency Task. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Emergency Task Today - Breaking & Trending Today

SIU investigating after man falls from apartment window during negotiations with Toronto police - Vimarsana News

SIU investigating after man falls from apartment window during negotiations with Toronto police

Ontario's police watchdog is investigating after a 32-year-old man in Toronto fell from an apartment window and died at the scene during negotiations with Toronto police Thursday evening.

Source: cbc.ca
WARMINGTON: Tensions high as person barricaded in Mississauga building - Vimarsana News

WARMINGTON: Tensions high as person barricaded in Mississauga building

It started with a call at 7:39 a.m. involving a man and the possibilty of a doctor being held hostage inside a medical building.

Source: canada.com
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome - Vimarsana News

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

MIAMI, Sept. 19, 2022 -- Veru Inc. , a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and... | September 19, 2022

Valeo and Veru sign agreement for sabizabulin to treat Covid-19 - Vimarsana News

Valeo and Veru sign agreement for sabizabulin to treat Covid-19

Valeo Pharma and Veru have signed a commercial services agreement in Canada for sabizabulin as a treatment for Covid-19.

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 - Vimarsana News

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression ... | September 13, 2022